Skip to main content

Advertisement

SpringerLink
Log in

Prognostic value of MMP-2 for patients with ovarian epithelial carcinoma: a systematic review and meta-analysis

  • Gynecologic Oncology
  • Published:
Archives of Gynecology and Obstetrics Aims and scope Submit manuscript

Abstract

Background

The reported roles of matrix metalloproteinase 2 (MMP-2) on the prognosis of patients with epithelial ovarian cancers (EOCs) are inconsistent.

Objective

This meta-analysis was performed to evaluate the prognostic significance of MMP-2 for patients with EOCs by analyzing 11 studies.

Methods

We systematically searched articles in the Cochrane Library, Pubmed, Embase, China National Knowledge Infrastructure (CNKI), Wanfang Database, and Chinese Biological Medical (CBM) Database, updated to February 1st 2015, with the following search terms: ovarian neoplasm OR ovarian tumor OR ovarian carcinoma OR ovarian malignance OR ovarian cancer AND matrix metalloproteinase-2 OR MMP-2.

Results

A total of 11 studies involving 1058 patients with EOCs were in accordance with the inclusion criteria. The pooled HR was 1.09 (95% CI 0.32–1.86, p = 0.006) in patients with overexpression of stromal MMP-2 with significant heterogeneity (I 2 = 53.1%, p = 0.074) between studies. For patients with MMP-2 overexpression in tumor cells, the pooled HR was 1.42 (95% CI 1.14–1.70, p = 0.000) with no significant heterogeneity (I 2 = 43.4%, p = 0.078) between studies. Sensitivity analyses were stable.

Conclusions

MMP-2 overexpression in tumor cells rather than stroma was significantly associated with poor prognosis in patient with endothelial ovarian cancer; however, the result remains to be confirmed with additional high-quality studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. American Cancer Society (2015) Cancer facts and figures 2015. American Cancer Society, Atlanta

    Google Scholar 

  2. Sun C, Li N, Ding D et al (2014) The role of BRCA status on the prognosis of patients with epithelial ovarian cancer: a systematic review of the literature with a meta-analysis. PLoS One 9:95285

    Article  Google Scholar 

  3. Torre LA, Bray F, Siegel RL et al (2015) Global cancer statistics, 2012. CA Cancer J Clin 65(2):87–108

    Article  PubMed  Google Scholar 

  4. Liu R, Lu S, Deng Y et al (2016) PSMB4 expression associates with epithelial ovarian cancer growth and poor prognosis. Arch Gynecol Obstet 293(6):1297–1307

    Article  CAS  PubMed  Google Scholar 

  5. Perigny M, Bairati I, Harvey I et al (2008) Role of immunohistochemical overexpression of matrix metalloproteinases MMP-2 and MMP-11 in the prognosis of death by ovarian cancer. Am J Clin Pathol 129:226–231

    Article  PubMed  Google Scholar 

  6. Sterne JA, Egger M (2001) Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol 54:1046–1055

    Article  CAS  PubMed  Google Scholar 

  7. Pan Y, Zhu D, Si WN et al (2008) Expressions of RhoC and MMP-2 proteins in epithelial ovarian cancer tissues and their clinical significances. J Jilin Univ Medicine Edition) 34:1042–1045

    CAS  Google Scholar 

  8. Kucukgoz GU, Gumurdulu D, Guzel AB et al (2014) Prognostic importance of survivin, Ki-67, and topoisomerase IIα in ovarian carcinoma. Arch Gynecol Obstet 289(2):393–398

    Article  Google Scholar 

  9. Peng H, Liu L, Zhao X (2013) Prognostic significance of matrix metalloproteinase-2 in gynecological cancer: a systemic review of the literature and meta-analysis. J BUON 18:202–210

    PubMed  Google Scholar 

  10. Horner MJ, Ries LAG, Krapcho M et al (2009) SEER Cancer Statistics Review, 1975–2006, National Cancer Institute. In: Bethesda, MD (ed) SEER Cancer Statistics Review

  11. Tierney JF, Stewart LA, Ghersi D et al (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8:16

    Article  PubMed  PubMed Central  Google Scholar 

  12. Yu L, Wang WY, Gan HY et al (2011) Expression and clinical significance of MMP-2 and MMP-7 in ovarian carcinoma. Chinese J Histochem Cytochem 20:325–329

    CAS  Google Scholar 

  13. Huang KJ, Sui LH (2012) The relevance and role of vascular endothelial growth factor C, matrix metalloproteinase-2 and E-cadherin in epithelial ovarian cancer. Med Oncol 29:318–323

    Article  CAS  PubMed  Google Scholar 

  14. Liu J, Ping W, Zu Y et al (2014) Correlations of lysyl oxidase with MMP2/MMP9 expression and its prognostic value in non-small cell lung cancer. Int J Clin Exp Pathol 7:6040–6047

    CAS  PubMed  PubMed Central  Google Scholar 

  15. Ekinci T, Ozbay PO, Yiğit S et al (2014) The correlation between immunohistochemical expression of MMP-2 and the prognosis of epithelial ovarian cancer. Ginekol Pol 85:121–130

    Article  PubMed  Google Scholar 

  16. Lynch CC (2011) Matrix metalloproteinases as master regulators of the vicious cycle of bone metastasis. Bone 48:44–53

    Article  CAS  PubMed  Google Scholar 

  17. Wen X, Liu H, Yu K et al (2014) Matrix metalloproteinase 2 expression and survival of patients with osteosarcoma: a meta-analysis. Tumour Biol 35:845–848

    Article  CAS  PubMed  Google Scholar 

  18. Su Z, Graybill WS, Zhu Y (2013) Detection and monitoring of ovarian cancer. Clin Chim Acta 415:341–345

    Article  CAS  PubMed  Google Scholar 

  19. Wu DB, Yang J, Yao YL et al (2013) Expression and clinical significance of MMP-2 and MMP-7 in ovarian carcinoma. Proceed Clin Med 22:650–652

    Google Scholar 

  20. Wells G, Shea B, Peterson J et al (2000) The Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 3rd symposium on systematic reviews: beyond the basics. pp 3–5

  21. Gentry-Maharaj A, Menon U (2012) Screening for ovarian cancer in the general population. Best Pract Res Clin Obstet Gynaecol 26:243–256

    Article  PubMed  Google Scholar 

  22. Sternlicht MD, Werb Z (2001) How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 17:463–516

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17:2815–2834

    Article  CAS  PubMed  Google Scholar 

  24. Wang XY, Zhang YK, Ren GH (2004) Relation between expression of MMP-2 and MMP-9 and invasion, metastasis of epithelial carcinoma of ovary. Chin J Oncol Rahabil 11:406–408

    Google Scholar 

  25. Westerlund A, Apaja-Sarkkinen M, Höyhtyä M et al (1999) Gelatinase A-immunoreactive protein in ovarian lesions- prognostic value in epithelial ovarian cancer. Gynecol Oncol 75:91–98

    Article  CAS  PubMed  Google Scholar 

  26. Torng PL, Mao TL, Chan WY et al (2004) Prognostic significance of stromal metalloproteinase-2 in ovarian adenocarcinoma and its relation to carcinoma progression. Gynecol Oncol 92:559–567

    Article  CAS  PubMed  Google Scholar 

  27. Kamat AA, Fletcher M, Gruman LM et al (2006) The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer. Clin Cancer Res 12:1707–1714

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Sillanpaa S, Anttila M, Suhonen K et al (2007) Prognostic significance of extracellular matrix metalloproteinase inducer and matrix metalloproteinase 2 in epithelial ovarian cancer. Tumour Biol 28:280–289

    Article  CAS  PubMed  Google Scholar 

  29. Wu X, Li H, Kang L et al (2002) Activated matrix metalloproteinase-2–a potential marker of prognosis for epithelial ovarian cancer. Gynecol Oncol 84:126–134

    Article  CAS  PubMed  Google Scholar 

  30. Davidson B, Reich R, Berner A et al (2001) Ovarian carcinoma cells in serous effusions show altered MMP-2 and TIMP-2 mRNA levels. Eur J Cancer 37:2040–2049

    Article  CAS  PubMed  Google Scholar 

  31. Chen VW, Bernardo R, Jeffrey L et al (2003) Pathology and classification of ovarian tumors. Cancer 97(10 Suppl):2631–2642

    Article  PubMed  Google Scholar 

  32. Yu WH, Woessner JF Jr, McNeish JD et al (2002) CD44 anchors the assembly of matrilysin/MMP-7 with heparin-binding epidermal growth factor precursor and ErbB4 and regulates female reproductive organ remodeling. Genes Dev 16:307–323

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Campo E, Merino MJ, Tavassoli FA et al (1992) Evaluation of basement membrane components and the 72 kDa type IV collagenase in serous tumors of the ovary. Am J Surg Pathol 16:500–507

    Article  CAS  PubMed  Google Scholar 

  34. Lydiksen L, Jensen-Fangel S, Blaakaer J (2014) Is it possible to define an optimal time for chemotherapy after surgery for ovarian cancer? Gynecol Oncol 133:454–459

    Article  CAS  PubMed  Google Scholar 

  35. Kessenbrock K, Plaks V, Werb Z (2010) Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141:52–67

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The study was supported by the National Natural Science Foundation of China (No. 81301556).

Author information

Authors and Affiliations

  1. Shandong Provincial Hospital Affiliated to Shandong University, No. 324, Road Jing Wu Wei Qi, Jinan, 250021, Shandong, China

    Honglei Jia, Fanxiao Liu & Dongsheng Zhou

  2. Qilu Hospital Affiliated to Shandong University, Jinan, 250012, Shandong, China

    Qingyu Zhang

Authors
  1. Honglei Jia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Qingyu Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fanxiao Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dongsheng Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dongsheng Zhou.

Ethics declarations

Conflict of interest

All authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of Shandong Provincial Hospital Affiliated to Shandong University and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jia, H., Zhang, Q., Liu, F. et al. Prognostic value of MMP-2 for patients with ovarian epithelial carcinoma: a systematic review and meta-analysis. Arch Gynecol Obstet 295, 689–696 (2017). https://doi.org/10.1007/s00404-016-4257-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00404-016-4257-9

Keywords

Search

Navigation